IMR Press / RCM / Volume 24 / Issue 11 / DOI: 10.31083/j.rcm2411335
Open Access Original Research
Clinical Effectiveness and Safety Comparison between Reduced Rivaroxaban Dose and Dual Antiplatelet Therapy for Nonvalvular Atrial Fibrillation Patients Following Percutaneous Left Atrial Appendage Closure: A Prospective Observational Study
Show Less
1 Department of Pharmacy, Zhongshan Hospital, Fudan University, 200032 Shanghai, China
2 Department of Cardiology, Zhongshan Hospital, Fudan University, 200032 Shanghai, China
*Correspondence: (Xiaochun Zhang); (Qianzhou Lv)
Rev. Cardiovasc. Med. 2023, 24(11), 335;
Submitted: 25 April 2023 | Revised: 30 May 2023 | Accepted: 12 June 2023 | Published: 27 November 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: Device-related thrombosis (DRT) after successful closure implantation on left atrial appendage (LAA) was considered as a major challenge and optimal strategy on antithrombotic therapy remains to be solved. This study was performed to compare the clinical effectiveness and safety of reduced rivaroxaban dose (RRD) and dual antiplatelet therapy (DAPT) after left atrial appendage closure (LAAC) implantation with the Watchman device. Methods: After successful LAAC, consecutive participants were medicated with a standard DAPT or RRD. The primary endpoints included DRT, thrombosis events (TE), and bleeding events that were documented during a 12-month follow-up period. Results: 767 patients (DAPT: n = 140; RRD: n = 627) were initially included. After propensity score matching (PSM), 140 patients treated with DAPT and 280 patients with RRD were included in each group with similar baseline information, thromboembolic and bleeding risk factors, cardiovascular risk factors and concomitant medication. In the RRD group, 193 patients were on rivaroxaban 15 mg (R15) and 47 received rivaroxaban 10 mg (R10). The incidence of DRT was documented in 12 (9.3%) patients in the DAPT group and 3 (6.3%) in R10 and 7 (3.0%) in R15 (log-rank p = 0.050). DAPT subgroups were more likely to experience shorter time to DRT as compared to R15 (R15vs. DAPT hazard ratio (HR) = 0.334, p = 0.015, 95% CI: 0.131–0.850). The median length of DRT in the R15 group was significantly lower than that of the DAPT group (1.721 [1.610–1.818] mm vs. 1.820 [1.725–1.925] mm, p = 0.029). Compared with the unadjusted estimated rates of ischemic events for patients with similar congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65–74 years, sex category (CHA2DS2-VASc) scores, a significant decrease of 68.6% in ischemic stroke rates was noted in the R15 group, which contributed to a 54.9% reduction of overall thromboembolic events. The overall minor bleeding was not significantly different amongst the three groups (p = 0.944). Procedural bleeding was more common in the DAPT group, as compared with the R10 and R15 groups. Conclusions: After successful closure implantation, long-term RRD significantly reduced the DRT and TE occurrence compared with DAPT.

clinical effectiveness and safety
reduced rivaroxaban dose
dual antiplatelet therapy
nonvalvular atrial fibrillation
left atrial appendage closure
Fig. 1.
Back to top